Free press releases distribution network?

Agency / Source: Gevo, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Gevo’s Isobutanol Secures EPA Registration - First Isobutanol to receive Environmental Protection Agency (EPA) registration as a fuel additive - Gevo.com
Gevo’s Isobutanol Secures EPA Registration

 

PRZOOM - /newswire/ - Englewood, CO, United States, 2010/11/11 - First Isobutanol to receive Environmental Protection Agency (EPA) registration as a fuel additive - Gevo.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Gevo, Inc., a privately held renewable chemicals and advanced biofuels company, announced today that it received notification that its isobutanol had successfully cleared registration with the U.S. EPA as a fuel additive. Gevo’s isobutanol is the first isobutanol to be listed in the EPA’s Fuel Registration Directory and is now approved for blending with gasoline.

"We’ve taken another important step in commercializing our product in the near term, said Gevo CEO Dr. Patrick Gruber. "Along with the chemicals market, selling isobutanol as a low Reid Vapor Pressure (RVP) biofuel blendstock is one of our most important opportunities."

Gevo believes isobutanol is a very attractive alcohol fuel gasoline blendstock. It has higher energy density than ethanol and lower RVP. RVP is regulated by the EPA under the Clean Air Act. Low RVP gasoline blends are required in many urban areas in order to comply with state level ozone attainment plans. Under the Renewable Fuel Standard II, isobutanol qualifies for 30 percent more renewable fuel value or Renewable Identification Number (RIN) than ethanol for obligated parties. Isobutanol has characteristics that make it an attractive alternative to other gasoline components like alkylate and aromatics, which should enable refiners to modify their gasoline formulation in ways that increase their operating margins. These various attributes also provide refiners with valuable options in meeting their clean air and renewable fuel obligations.

Gevo’s isobutanol can be used directly as a specialty chemical, as a gasoline and jet fuel blendstock, and through conversion into plastics, fibers, rubber and other polymers. Gevo will soon begin the retrofit of its first 22 million gallons per year (MPGY) ethanol facility in Luverne, MN to produce 18 MGPY of isobutanol. The Company plans to expand its isobutanol production via the retrofit of additional ethanol facilities over the next few years. In the future, Gevo intends to produce cellulosic isobutanol once biomass conversion technology is commercially available.

About Gevo

Gevo (gevo.com) is developing capital efficient biorefinery systems to provide renewable, cost-effective building block products to the fuel and chemical industries. The Company seeks to convert renewable raw materials into isobutanol and renewable hydrocarbons that can be directly integrated on a “drop in” basis into existing fuel and chemical products to deliver environmental and economic benefits. Gevo is committed to a sustainable biobased economy that meets society’s needs for plentiful food and clean air and water.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Gevo, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Gevo’s Isobutanol Secures EPA Registration

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Shweta Agarwal - Schwartz Communications 
781-684-0770 gevo[.]schwartzcomm.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Gevo, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Gevo, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today